10x Genomics, Inc.
TXG
Rang in Aktien
#2231
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012... Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Aktienkurs
$69.74
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$9.09B
Veränderung (1 Tag)
-3.67%
Veränderung (1 Jahr)
489.48%
Land
US
Handel 10x Genomics, Inc. (TXG)
Kategorie
Healthcare
Operative Marge für 10x Genomics, Inc. (TXG)
Operative Marge zum October 2026 TTM: -14.33%
Laut den neuesten Finanzberichten und dem Aktienkurs von 10x Genomics, Inc. beträgt die aktuelle operative Marge (TTM) -14.33%. Am Ende des Jahres 2023 lag die operative Marge bei -42.88%.
Historie der operativen Marge von 10x Genomics, Inc. von 2017 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | -14.33% | -55.01% |
| 2024 | -31.85% | -25.72% |
| 2023 | -42.88% | 31.86% |
| 2022 | -32.52% | 201.39% |
| 2021 | -10.79% | -62.21% |
| 2020 | -28.55% | 141.54% |
| 2019 | -11.82% | -84.39% |
| 2018 | -75.70% | 192.84% |
| 2017 | -25.85% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 12.70% | -100.89% |
US
|
|
| 74.94% | -105.23% |
AU
|
|
| 3.33% | -100.23% |
US
|
|
| -19.76% | -98.62% |
US
|
|
| 0.00% | - |
US
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.